Journal of General Internal Medicine

, Volume 21, Issue 7, pp C11–C13

Stauffer’s syndrome variant with cholestatic jaundice

A case report
Case Report


Cholestasis is a common feature of several malignant diseases, including pancreatic, hepatic, gallbladder, and ampullary carcinomas. It is usually secondary to main bile duct obstruction or widespread hepatic metastasis, but it can also be a paraneoplastic syndrome of other underlying malignancies. Stauffer’s syndrome is a rare paraneoplastic manifestation of renal cell carcinoma (RCC) that is characterized by elevated alkaline phosphatase, erythrocyte sedimentation rate, α-2-globulin, and γ-glutamyl transferase, thrombocytosis, prolongation of prothrombin time, and hepatosplenomegaly, in the absence of hepatic metastasis and jaundice. A rare variant of this syndrome with jaundice has recently been described in 3 cases in the literature. We report a patient who presented with abdominal pain and cholestatic jaundice in whom RCC was incidentally found during initial workup. Jaundice and liver dysfunction resolved completely after surgical resection of the tumor. This case illustrates the protean manifestations of RCC, and the importance of considering Stauffer’s syndrome and its variant in the differential diagnosis of anicteric and icteric cholestasis, which may allow early recognition and treatment of an underlying malignancy.

Key words

jaundice cholestasis renal cell carcinoma Stauffer’s syndrome 


  1. 1.
    Sharara AI, Panella TJ, Fitz JG. Paraneoplastic hepatopathy associated with soft tissue sarcoma. Gastroenterology. 1992;103:330–2.PubMedGoogle Scholar
  2. 2.
    Karakolios A, Kasapis C, Kallinikidis T, Kalpidis P, Grigoriadis N. Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol. 2003;1:480–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Saintigny P, Spano JP, Tcherakian F, Pailler MC, Breau JL. Non-metastatic intrahepatic cholestasis associated with bronchial adenocarcinoma. Ann Med Interne (Paris). 2003;154:171–5.Google Scholar
  4. 4.
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29.PubMedCrossRefGoogle Scholar
  5. 5.
    Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF. Diagnosis and management of renal cell carcinoma. A clinical and pathological study of 309 cases. Cancer. 1971;28:1165–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Gold P, Fefer A, Thompson J. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol. 1996;14:216–22.PubMedGoogle Scholar
  7. 7.
    Stauffer MH. Nephrogenic hepatomegaly. Gastroenterology. 1961;40:694.Google Scholar
  8. 8.
    Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer. 1997;72:424–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Dourakis SP, Sinani C, Deutsch M, Dimitriadou E, Hadziyannis SJ. Cholestatic jaundice as a paraneoplastic manifestation of renal cell carcinoma. Eur J Gastroenterol Hepatol. 1997;9:311–4.PubMedGoogle Scholar
  10. 10.
    Giannakos G, Papanicolaou X, Trafalis D, Michaelidis I, Margaritis G, Christofilakis C. Stauffer’s syndrome variant associated with renal cell carcinoma. Int J Urol. 2005;12:757–9.PubMedCrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2006

Authors and Affiliations

  1. 1.Department of Medicine, Division of Pulmonary/Critical CareUniversity of Miami-Miller School of MedicineMiamiUSA
  2. 2.Jackson Memorial Hospital, Department of MedicineUniversity of Miami-Miller School of MedicineMiamiUSA

Personalised recommendations